Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,055.95
(
-0.75%
)
US TECH 100
25,719.40
(
-0.59%
)
Dow Jones
49,072.08
(
-0.76%
)
Brent Oil
96.33
(
6.23%
)
Bitcoin
74,985.55
(
-1.19%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

GrthzGd

Send PM Follow Ignore
Followers 15
Posts 1612
Boards Moderated 1
Alias Born 09/07/2010

GrthzGd

Re: DewDiligence post# 186389

Wednesday, 01/21/2015 12:55:25 PM

Wednesday, January 21, 2015 12:55:25 PM

Post# of 257432

Regarding the HCV pipeline, ENTA is seeking to develop a wholly owned 2-drug regimen consisting of a nuke + NS5A, a cyclophilin inhibitor (CI) + NS5a, or—the most exciting option, IMO—a nuke + CI.

Could such a combination potentially reach the ~7% of HCV sufferers not being cured now by GILD or ABBV?
Also, what about HBV, which I understand is quite a problem in Europe, and for which tehre is still no cure. Could their drugs reach that?

"The curious task of economics is to demonstrate to men how little they really know about what they imagine they can design." -F.A. von Hayek

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today